Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA Adverse Event Reporting System
Choosing the right ASMs requires consideration of the type of epilepsy, the individual tolerance and potential severe toxicity of different medications. Although the disproportionality analysis is a hypothesis generating, we provide a reference for the clinical safety of CNB and LCM.
Authors
- Zhirui Song
- Qiang Chang (ORCID: https://orcid.org/0000-0002-7625-2170)
- Weiliang Li (ORCID: https://orcid.org/0009-0002-0051-8152)
- Dongxin Chen (ORCID: https://orcid.org/0000-0001-8421-0889)
- Yan Zhao (ORCID: https://orcid.org/0000-0002-6148-5908)
- Airong Yu (ORCID: https://orcid.org/0000-0001-8254-1051)
- Shenglan Shang (ORCID: https://orcid.org/0000-0002-2771-6100)
- Chen Zhou (ORCID: https://orcid.org/0000-0002-2707-2624)
- Zhou Fan (ORCID: https://orcid.org/0000-0003-3067-3540)
- Xiang Lu (ORCID: https://orcid.org/0000-0003-4781-1997)
- Zhe Yu (ORCID: https://orcid.org/0000-0002-1401-2294)
Institutions
- Wuhan University of Technology (CN)
- Central Hospital of Wuhan (CN)
- Wuhan General Hospital of Guangzhou (CN)
- Wuhan University of Science and Technology (CN)
- General Hospital of Central Theater Command
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.3389/fneur.2025.1625612
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation